CSIMarket Company Name, Ticker, Suppliers, else..
 
Bicara Therapeutics Inc   (NASDAQ: BCAX)
 
Price: $17.6300 $-0.57 -3.132%
Day's High: $18.957500457763672 Week Perf: -6.22 %
Day's Low: $ 17.56 30 Day Perf: -25.17 %
Volume (M): 751,030 52 Wk High: $ 30.99
Volume (M$): $ 0 52 Wk Avg: $20.46
Open: $18.50 52 Wk Low: $13.70



 Market Capitalization (Millions $) 1,198
 Shares Outstanding (Millions) 68
 Employees 103
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -185
 Cash Flow (TTM) (Millions $) -113
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company is a clinical-stage biopharmaceutical firm focused on the development and commercialization of ficerafusp alfa and other product candidates. It conducts preclinical studies and clinical trials, utilizing third parties and collaborators to obtain regulatory approval and advance its products to market. The company faces risks associated with clinical development, regulatory approval, competition, and financial challenges.


   Company Address: 116 Huntington Ave Boston 2116 MA
   Company Phone Number: 468-4219   Stock Exchange / Ticker: NASDAQ BCAX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Bicara Therapeutics Ficerafusp Alfa Secures FDA Breakthrough Designation A Promising Horizon for HPV-Negative R/M ...

Published Tue, Oct 14 2025 9:01 AM UTC

In a significant stride within the realm of oncology, Bicara Therapeutics Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its investigational therapy, ficerafusp alfa, for the treatment of first-line human papillomavirus (HPV)-negative recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Th...
Announcement

Bicara Therapeutics Navigating Challenges and Opportunities in Biopharmaceutical Development

Published Tue, Jun 3 2025 8:39 PM UTC

: Bicara Therapeutics Inc. (NASDAQ: BCAX), a clinical-stage biopharmaceutical venture, is poised to present its groundbreaking work in bifunctional therapies at the upcoming Goldman Sachs 46th Annual Global Healthcare Conference. Despite recent challenges in stock performance and clinical data, the company continues to advance its pipeline for treating solid tumors, with a ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 2.55
PEG (TTM) -

Financial Strength Current
Quick Ratio 11.44
Working Capital Ratio 11.59
Leverage Ratio (MRQ) 0.09
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.1 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 7.32 $
Book Value 6.9 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,799,641
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.